Hereditary hemochromatosis

Annals of Clinical and Laboratory Science

Volumn 28, Issue 5, 1998, Pages 300-312

  Walker Jr , Ernest M ^a   Wolfe, Melanie D ^b   Norton, Michael L ^b   Walker, Sandra M ^a   Jones, Mark M ^c  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARSHALL UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; HEMOSIDERIN; IRON;

ARTICLE; CHROMOSOME 6; EARLY DIAGNOSIS; GENE LOCUS; GENETIC RISK; HEALTH CARE COST; HEMOCHROMATOSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON ABSORPTION; LIVER BIOPSY; PRIORITY JOURNAL;

ADULT; AGE FACTORS; BIOLOGICAL TRANSPORT; CHELATING AGENTS; HEMOCHROMATOSIS; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; IRON; MASS SCREENING; PHLEBOTOMY; SEX FACTORS;

EID: 3543142318     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Powell LW, Summers KM, Halliday JW. Ch. 21. Hemochromatosis. In: Haubrich WS, Schaffner F, Beck JE, editors. Gastroenterology, 5th ed., Vol 3. Philadelphia: WB Saunders Co., 1994:2325-9.
2. Fairbanks VF, Klee GG. Biochemical Aspects of Hematology. In: Tietz RW, editor. Textbook of Clinical Chemistry, 1st ed. Philadelphia: WB Saunders Co., 1986:1495-588.
3. Edwards CQ, Griffen LM, Kushner JP. Disorders of excess iron. Hosp Pract: Symposium Supplement 1991;26(suppl. 3):30-6.
4. Crosby WH. Physiology and pathophysiology of iron metabolism. Hosp Pract: Symposium Supplement 1991;26(suppl. 3):7-10.
5. Bothwell T. The importance of assessing iron status. Hosp Pract: Symposium Supplement 1991;26(suppl. 3):11-6.
6. Teichmann R, Stremmel W. Iron uptake by human upper small intestine microvillus membrane vesicles. Indication for a facilitated transport mechanism mediated by a membrane iron-binding protein. J Clin Invest 1990;86:2145-53.
7. Bacon BR, Britton RS. Hereditary hemochromatosis. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Vol 2, 6th ed. Philadelphia: WB Saunders Co., 1998:1097-103.
8. Wight DGD. Haemochromatosis and iron storage disorders. In: Gresham GA, Consultant Editor. Histopathology, Vol 4: Atlas of Liver Pathology, Philadelphia: Lippincott, 1982:107-17.
9. Goodman ZD and Ishak KG. Medical diseases of the liver. In: Silverberg SG, editor. Principles and Practice of Surgical Pathology and Cytopathology. Vol 2, 3rd ed., New York: Churchill-Livingstone, 1997:1867-939.
10. Witte DL, Crosby WH, Edwards CQ, et al. Hereditary hemochromatosis. Clin Chem Acta 1996;245: 139-200.
11. Shalev O, Hebbel RP. Extremely high avidity association of Fe (III) with Sickle Red Cell Membrane. Blood 1996;88:349-52.
12. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89: 739-61.
13. Raja KB, Pountney D, Bomford A, Przemioslo R, Sherman D, Simpson RJ, Williams R, Peters TJ. A duodenal mucosal abnormality in the reduction of Fe (III) in patients with genetic hemochromatosis. Gut 1996;38:765-9.
14. Simon M, Alexander JL, Fauchet R, Genetet B, Bourel M. The genetics of haemochromatosis. Prog Med Genet 1980;4:135-68.
15. Gambino R. Routine screening for iron status. Hosp Pract: Symposium Supplement 1991;26(suppl. 3): 41-4.
16. Scheuer PJ, Williams R, Muir AR. Hepatic pathology in relatives of patients with haemochromatosis. J Path Bact 1962;84:53-64.
17. Fairbanks VF. Laboratory testing for iron status. Hosp Pract: Symposium Supplement 1991;26(suppl. 3): 17-24.
18. Searle J, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In: MacSween RNM, Anthony PP, Scheuer PJ, et al. editors. Pathology of the liver, 3rd ed. New York: Churchill-Livingstone, 1994:219-41.
19. Powell LW, Kerr JFR. The pathology of the liver in hemochromatosis. Pathobiol Annu 1975;317-37.
20. Haddow JE, Ledue TB. Preventing manifestations of hereditary haemochromatosis through population based screening. J Med Screen 1994;1(1):16-21.
21. Moss AA. Computed axial tomographic scanning. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal Disease-Pathophysiology, Diagnosis, Management, 3rd ed. Philadelphia: WB Saunders 1983:1707.
22. Jensen PD, Jensen FT, Christensen T, Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br J Haematol 1994;84(1):171-84.
23. Marti-Bonmati L, Baamonde A, Poyatos CR, Monteagudo E. Prenatal diagnosis of idiopathic neonatal hemochromatosis with MRI. Abdom Imaging 1994;19(1):55-6.
24. Blankenberg F, Eisenberg S, Scheinman MN, Higgins CB. Use of cine gradient echo (GRE) MR in the imaging of cardiac hemochromatosis. J Comput Assist Tomogr 1994;18(1):136-8.
25. Bonetti MG, Castriota-Scanderbeg A, Criconia GM, Mazza P, Sacco M, Amurri B, Masi C. Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. Pediatr Radiol 1996;26(9):650-6.
26. Thomsen C, Wiggers P, Ring-Larsen H, Christiansen E, Dalhoj J, Henriksen O, Christoffersen P. Identification of patients with hereditary haemochromatosis by magnetic resonance imaging and spectroscopic relaxation time measurements. Magn Reson Imaging 1992;10(6):867-79.
27. Lattanzi F, Bellotti P, Picano E, Chiarella F, Mazzarisi A, Melevendi C, Forni G, Landini L, Distante A, Vecchio C. Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation 1993;87:748-54.
28. Kozlov AV, Bini A, Gallesi D, Giovannini F, Iannone A, Masini A, Meletti E, Tomasi A. "Free" iron, as detected by electron paramagnetic resonance spectroscopy, increases unequally in different tissues during dietary iron overload in the rat. Biometals 1996;9(1):98-103.
29. Gerlach M, Trautwein AX, Zecca L, Youdim MB, Riederer P. Mossbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 1995;65(2):923-6.
30. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P, Kosty M, Venditti CP, Phatak PD, Seese NK, Chorney KA, Ten Elshof AE, Gerhard GS, Chorney M. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996;22: 187-94; discussion 194a-194b.
31. Woolley AT, Hadley D, Landre P, deMello AJ, Mathies RA, Northrup MA. Functional integration of PCR amplification and capillary electrophoresis in a microfabricated DNA analysis device. Anal Chem 1996;68:4081-6.
32. Woolley AT, Sensabaugh GE, Mathies RA. High speed DNA genotyping using microfabricated capillary array electrophoresis chips. Anal Chem 1997;69: 2181-6.
33. Merryweather-Clarke AT, Pointon JJ, Sherman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
34. Weinberg ED. The iron-withholding defense system. ASM 1993;59:559-62; Boelaert JR. Iron and infection (editorial). Acta Clin Belg 1996;51:213-21.
35. Weinberg ED. The iron-withholding defense system. ASM 1993;59:559-62; Boelaert JR. Iron and infection (editorial). Acta Clin Belg 1996;51:213-21.
36. Boelaert JR, Weinberg ED, Weinberg GA. Altered iron metabolism in HIV infection: mechanisms, possible consequences and proposals for management. Infect Agents Dis 1996;5:36-46.
37. Daly AL, Velazquez LA, Bradley S, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med 1989;87:468-71.
38. Robins-Browne RM, Prpic JK. Effects of iron and deferoxamine on infections with Yersinia enterocolitica. Infection and Immunity 1985;47:774-9.
39. Bullen JJ, Spaulding PB, Ward CG, Gutteridge JM. Hemochromatosis, iron, and septicemia caused by Vibrio vulnificus. Arch Intern Med 1991;151:1606-9.
40. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fe d'Ostiani C, Bistoni F, Romani L. Iron overload alters innate and T-helper cell responses to Candida albicans in mice. J Infect Dis 1997;175:1467-76.
41. Bacon BR. Diagnosis and management of hemochromatosis. Gastroenterology 1997;113:995-9.
42. Worwood M, Dorak Mt, Nicklin S, Stone C, Pointon J, Darke C. The frequency of the haemochromatosis-associated genotype D6S265-1:D65105-8 in blood donors. Br J Haematol 1996;93:838-40.
43. Gandon G, Jouanolle AM, Chauvel B, Mauvieux V, le-Treut A, Feingold J, LeGall JY, David V, Yaouanq J. Linkage disequilibrium and extended haplotypes in the HLA-A to D6t105 region: implications for mapping the hemochromatosis gene (HFE). Hum Genet 1996;97:103-13.
44. Raha-Chowdhury R, Bowen DJ, Worwood M. A new highly polymorphic marker in the 5′ untranslated region of the HLA-F shows strong allelic association with haemochromatosis. Hum Genet 1996;97:228-31.
45. Lauer P, Meyer NC, Prass CE, Starnes SM, Wolff RK, Gnirke A. Clone-contig and STS maps of the hereditary hemochromatosis region on the human chromosome 6p21.3-p22. Genome Res 1997;7: 456-70.
46. Burt MJ, Smit DJ, Pyper WR, Powell LW, Jazwinsa EC. A 4.5-megabase YAC contig and physical map over the hemochromatosis gene regions. Genomics 1996;33:153-8.
47. Author unknown. Haemoehromatosis . . . definite maybe? Nature Genetics 1996;13(4):375-6.
48. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13: 399-408.
49. Riedel H-D, Stremmel W. The haemochromatosis gene. J Hepatology 1997;26:941-4.
50. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, Schatzman RC. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-7.
51. Merryweather-Clark AT, Ponton JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-8.
52. Roeckel IE, Dickson LG. Understanding iron absorption and metabolism, aided by studies of hemochromatosis. Ann Clin Lab Sci 1998;28:30-3.
53. Herbert V. Introduction and medicolegal considerations. Hospital Practice: Symposium Supplement 1991;26(suppl. 3):4-6.
54. Little DR. Hemochromatosis: Diagnosis and management. Am Fam Physician 1996;53(3):2623-8.
55. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1996;332: 918-22.
56. Kontoghiorghes GJ. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs. Toxicol Letters 1995;80: 1-18.
57. Klassen CD. Heavy metals and heavy-metal antagonists. In: Hardman JG, Limbird LE, editors. The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996:1649-71.
58. Physicians Desk Reference: Product Information, 50th ed. Montvale, NJ: Medical economics. Data Production Co. 1996:320-1.
59. Kontoghiorghes G. New concepts of iron and aluminum chelation therapy with oral L1 (deferiprone) and other chelators. Analyst 1995;120:845-51.
60. Swartz RD, Legault DJ. Long-term intraperitoneal deferoxamine for hemochromatosis. Am J Med 1996; 100:308-12.
61. Lambardo T, Ferro G, Frontini V, Percolla S. High-dose intravenous desferrioxamine delivery in four thalassemic patients allergic to subcutaneous DFO administration. Am J Hematol 1996;51:90-2.
62. Olivieri NF. For the Toronto Iron Chelation Group: Randomized trial of deferiprone (L1) and deferoxamine in thalassemia major. Blood 1996;88(suppl. 1):651a abstract.
63. Balan V, Baldus W, Fairbanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis: cost-effectiveness study based on 12,258 patients. Gastroenterology 1994;107:453-9.
64. Fairbanks VF. Laboratory testing for iron status. Hospital Practice: Symposium Supplement 1991;26(suppl. 3):17-24.
65. Cox T. Hemochromatosis: strike while the iron is hot. Nature Genet 1996;13:386-8; Riedel H-D, Stremmel W. The haemochromatosis gene. J Hepatology 1997; 26:941-4.
66. Cox T. Hemochromatosis: strike while the iron is hot. Nature Genet 1996;13:386-8; Riedel H-D, Stremmel W. The haemochromatosis gene. J Hepatology 1997; 26:941-4.
67. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.